Background/Aims: Hepatocellular carcinoma (HCC) remains a difficult problem that significantly affects the survival of the afflicted patients. Accumulating evidence has demonstrated the functions of long non-coding RNA (lncRNA) in HCC. In the present study, we aimed to explore the potential roles of PVT1 in the tumorigenesis and progression of HCC. Methods: In this study, quantitative reverse transcription-polymerase chain reaction (RTqPCR) was applied to detect the differences between PVT1 expression in HCC tissues and cell lines. Then, the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were searched to confirm the relationship between PVT1 expression and HCC. Moreover, a meta-analysis comprising TCGA, GEO, and RT-qPCR was applied to estimate the expression of PVT1 in HCC. Then, cell proliferation was evaluated in vitro. A chicken chorioallantoic membrane (CAM) model of HCC was constructed to measure the effect on tumorigenicity in vivo. To further explore the sponge microRNA (miRNA) of PVT1 in HCC, we used TCGA, GEO, a gene microarray, and target prediction algorithms. TCGA and GEO and the gene microarray were used to select the differentially expressed miRNAs, and the different target prediction algorithms were applied to predict the target miRNAs of PVT1. Results: We found that PVT1 was markedly overexpressed in HCC tissue than in normal liver tissues based on both RTqPCR and data from TCGA, and the overexpression of PVT1 was closely related to the gender and race of the patient as well as to higher HCC tumor grades. Also, a meta-analysis of 840 
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Introduction
Hepatocellular carcinoma (HCC) represents one of the most widespread malignancies, with extremely high rates of cancer-related deaths [1] . The majority cases are clustered in Asia and Africa, and half of these incidences and deaths have occurred in China due to chronic hepatitis B infections [1] . Though the most curative treatment is surgery, including tumor resection and liver transplantation, the high rates of postoperative recurrence and mortality remain the main obstacle for the longer survival of patients with HCC [2] [3] [4] . Taking these into consideration, it is essential to elucidate the mechanism underlying HCC, which might provide novel insights into the diagnosis and treatment of HCC patients.
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts with lengths longer than 200 nucleotides [5] . It has been indicated has lncRNAs could affect different cellular functions and participate in various physiological and pathological progress [6] . Accumulating evidence has shown that the ectopic expression of lncRNAs could influence the progression of HCC by modulating the self-renewal ability of liver cancer stem cells (CSCs) and other biological functions, including proliferation, apoptosis, invasion, and metastasis [7] [8] [9] [10] . Moreover, other articles have also reported that the aberrant expression of lncRNAs might be involved in regulating the chemotherapy resistance of HCC patients [11, 12] . The lncRNA PVT1 is located at chromosome 8q24, which is known to be a cancer-related region [13] . Moreover, PVT1 functions as an oncogene via interacting with MYC, encoding microRNA (miRNA), and participating in DNA rearrangement [14] . Several studies have identified PVT1 overexpression could accelerate the development of cancers and reduce the sensitivity of cancer patients to chemistry [15] [16] [17] [18] [19] [20] . It has been previously shown that PVT1 was highly expressed in HCC compared with non-tumor tissues, and its overexpression predicts recurrence by our group and other groups [21] . We had also surveyed the genetic regulatory network of PVT1 in HCC through a gene microarray and RNAsequecing data mining with bioinformatics method to investigate the potential mechanism of PVT1 in HCC, and found that DLC1 and the Hippo signaling pathway could be closely related to the function of PVT1 in HCC [21] ; however, the functions of PVT1 in HCC remain still elusive. In the present study, we sought to explore Fig. 1 . A flow chart of this study. 
PVT1 and HCC: A Meta-analysis
The HCC-related PVT1 microarrays from GEO (http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) were downloaded. The criteria used to determine study eligibility were as follows: 1) the study must be published in English and be a full essay; 2) it must include patients with HCC; 3) it must investigate the correlation of PVT1 expression with HCC; 4) it must use a prospective or retrospective cohort design with a clearly defined source population and justify all excluded eligible cases; 5) false positives, false negatives, true positives, and true negatives were provided or could be calculated from the data; and 6) when the same or similar samples of patients were investigated in several publications, the latest and most complete study was selected to avoid duplication. Also, the RNA-Seq datasets in TCGA (https://cancergenome.nih.gov/) database were used, which was updated up to 30th September, 2017. Furthermore, we conducted an RT-qPCR that we included in the meta-analysis. In addition, publications related to PVT1 in HCC were chosen from 12 online databases: PubMed, Embase, Google Scholar, Web of Science, Ovid, LILACS, Wiley Online Library, Science Direct, Chong Qing VIP, Cochrane Central Register of Controlled Trials, Wan Fang, Chinese CNKI, and China Biology Medicine disc. The retrieval was performed using the following keywords: PVT1 AND (hepatocellular OR liver OR hepatic OR HCC) AND (malignan* OR cancer OR tumor OR tumour OR neoplas* OR carcinoma). The literature retrieval was evaluated and crosschecked by two authors (Jia-cheng Huang and Peng Lin). If there was a disagreement, the group convened and discussed.
Microarray Analysis
To further survey the functions of PVT1 in HCC cells, Agilent's Human Gene Expression 4x44K Microarrays (v2) were applied to the PVT1-decreased SMMC-7721 cells and control cells. The Agilent Feature Extraction software (version 11.0.1.1) was utilized to obtain the original data, and the GeneSpring GX v12.1 software package (Agilent Technologies) was used to normalize and analyze the original data. We considered the genes to be significantly different when the fold change was ≥ 2 and P value was ≤ 0.05. In addition, we also conducted gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses using the GeneSpring GX v12.1 software package, which enabled us to understand the biological pathways related to the differentially expressed genes.
Identification of the Corresponding miRNAs or Genes Associated with PVT1
To further explore the corresponding miRNAs and genes associated with PVT1, the GEO and TCGA databases were used to further investigate the differentially expressed miRNAs or genes [24] [25] [26] . The differentially expressed miRNAs in the GEO database were chosen using the described vote-counting strategy [27] . In addition, four lncRNA/miRNA prediction algorithms were applied to predict the potential target miRNAs of PVT1. The four corresponding prediction algorithms were Tarbase (http://diana.imis. athena-innovation.gr/), starBase (http://starbase.sysu.edu.cn/), lncACTdb (http://210.46.85.180:8080/ LncACTdb/), and TANRIC (http://ibl.mdanderson.org/tanric/_design/basic/index.html). In addition, 12 target prediction algorithms were used to predict the potential target genes of the miRNAs. The 12 corresponding prediction algorithms were DIANA microT v4 (http://diana.imis.athena-innovation.gr/), miRDB (http://www.mirdb.org/), miRWalk (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), miRmap (http://mirmap.ezlab.org/), miRanda (http://www.microrna.org), miRBridge (http://mirsystem. cgm.ntu.edu.tw/), PicTar2 (https://www.mdc-berlin.de/), miRNAMap (http://mirnamap.mbc.nctu.edu. tw/), RNA22 (https://cm.jefferson.edu/), PITA (https://genie.weizmann.ac.il/), TargetScan (http://www. targetscan.org/), and RNAhybrid (https://bibiserv.cebitec.uni-bielefeld.de/).
In this study, the downregulated miRNAs in the GEO and TCGA databases and the miRNAs selected by the target prediction algorithms were used to identify PVT1's corresponding miRNAs. Also, the upregulated genes in the GEO and TCGA databases, the downregulated genes identified from the microarray analysis after silencing PVT1 expression, and the genes selected by the target prediction algorithms were used to select the corresponding genes. In this process, Venn diagrams (http://bioinformatics.psb.ugent.be/ webtools/Venn/) were used to identify overlapping miRNAs or genes associated with PVT1 [28, 29] .
Validation of the Expression of PVT1/miRNA/mRNA
In this study, RNA-Seq data, calculated on the Illumina HiSeq RNA-Seq platform, was obtained from TCGA, including 374 HCC tissues and 50 non-tumor tissues. The expression data were exhibited as reads 
Cell Proliferation
In our current study, cell proliferation was evaluated through an MTT assay. Briefly, SMMC-7721 cells were washed twice with PBS when the cell , density reached 80%. The cell suspension was fabricated after being digested by trypsin, and then, cells were seeded into 96-well plates with 200 μL of volume per well, each of which containing 3 × 10 3 −6 × 10 3 cells. Subsequently, MTT (20 μL, 5 mg/mL; Sigma, USA) was seeded into each well, and the cells were then incubated at 37°C with 5% CO 2 for 4 h. Dimethyl sulfoxide (DMSO; 150 μL) was placed into each well, and the cells were softly shaken for nearly 10 min to dissolve the crystal. A microplate reader was applied to distinguish the absorbance value at 490 nm at 12 h, 24 h, 48 h, 72 h, and 96 h.
Cell viability was evaluated through the fluorimetric detection of resorufin (CellTiter-Blue Cell Viability Assay, Promega, Madison, WI, USA) further confirm the results of the MTT assay. The procedure was performed based on the manufacturer's instructions. An FL600 fluorescence plate reader (Bio-Tek, Winooski, VT, USA) was applied for fluorimetry (excitation = 560 nm, emission = 590 nm). Fluorescence data were calculated as the fluorescence of treated sample/mock control×100%.
Chorioallantoic Membrane Model of HCC
Fertilized chicken eggs were purchased from a local hennery where they had been stored at 10°C and were then incubated at 37°C. Then, SMMC-7721 cells from three groups (blank group, negative control, and the PVT1 siRNA group) were seeded into the chicken embryo chorioallantoic membrane (CAM; 2.5 × 106 cells per egg) after eight days of incubation in an incubator. Five chicken eggs were included in each group. Subsequently, the tumor growth and embryo viability were observed daily through the SZ61 Zoom Stereo Microscope (Olympus, Japan). The tumor xenografts were carefully removed from the CAMs, fixed with paraformaldehyde and embedded in paraffin after five days [30] . The size of the tumor xenografts was recorded, and the xenografts' sizes were recorded as 0 if the length of the xenograft was less than 0.2 cm.
The Potential Pathways Associated with PVT1 and miRNAs
To further investigate the fundamental functions and pathways associated with PVT1 and miRNAs in HCC, bioinformatics analyses, including GO and KEGG analyses, were performed as described [31, 32] . Genes with more than three overlapping nucleotide sequences (either those genes listed as overexpressed in the GEO database and TCGA, shown to be downregulated in the gene microarray, or identified as the target genes of miR-424-5p by more than five prediction algorithms) were used for bioinformatics analysis. The Database for Annotation, Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf. gov/) was used for GO and KEGG analyses. Three independent categories (biological process [BP], cellular component [CC] , and molecular function [MF]) were derived separately from the GO analysis. Also, a GO functional network was constructed via Cytoscape (v2.8, http://cytoscape.org).
Statistical Analysis
A statistical analysis was carried out using SPSS v22.0. A Student's t-test was conducted to discover the difference between two groups, and Kruskal-Wallis H test was used to estimate the relationship between three or more groups. The summary statistics between the different groups were exhibited as mean ± standard deviation (mean ± SD). A ROC curve was drawn to distinguish HCC from normal liver tissues by gene expression. Statistical significance was considered to be a P value was lower than 0.05 (two sides). In addition, all experiments were repeated six times. 
Results
PVT1's Upregulation in HCC Tissues and Cells and Its Association with Clinical Pathological Factors
To investigate the differential expression of PVT1 in HCC and non-cancerous liver tissue, an RT-qPCR was performed. The results showed that PVT1 was remarkably upregulated in HCC tissues compared with the corresponding normal tissues (P < 0.001; Fig. 2A ). Also, we conducted a ROC curve analysis to confirm the value of PVT1 in HCC. The area under the curve (AUC) of PVT1 was 0.857 (95% confidence interval [CI] 0.775~0.939; P < 0.001; Fig.  2B ), and the sensitivity and specificity were 0.775 and 0.939, respectively. Furthermore, in comparison with the L02 cell line, PVT1 was overexpressed in HCC tumor cell lines, especially SMMC-7721 (P = 0.025) and Bel-7404 (P = 0.049; Fig. 2C ). In addition, to further confirm the high expression of PVT1 in HCC tissues and its potential role in the progression of HCC, we searched TCGA for relevant tissue data, resulting in 374 HCC tissues and 50 non-tumor tissues. Compared with the corresponding normal tissues, PVT1 was overexpressed in HCC tissues (P < 0.001; Fig. 2D ). Moreover, the AUC of PVT1 was 0.822 (95% CI 0.780~0.863; P < 0.001; Fig. 2E ), and the sensitivity and specificity were 0.780 and 0.863, respectively, confirming the results of the RT-qPCR. As shown in Table 1 , the expression level of PVT1 was higher in male patients than in female patients, and it was also higher in Asian patients than in white or black patients (P < 0.05; Fig. 2F , 2G). Compared with the corresponding control groups, PVT1 was also increased in HCC patients with advanced pathological grades (P = 0.003; Fig. 2H ). Additionally, we investigated the role of PVT1 expression in patients' survival. It was observed that patients with low PVT1 expression survived for longer (64.31 ± 5.17 months) compared to patients with high PVT1 expression (59.59 ± 4.75 months; P = 0.241; Fig. 2I ). These results suggest that lncRNA PVT1 might serve as an oncogene for HCC.
In addition, seven datasets in the GEO database (GSE54236, GSE49515, GSE60502, GSE58208, GSE98269, GSE57957, and GSE49713) were selected, and their expression data was used to evaluate PVT1 expression. As results, we found that PVT1 was upregulated in datasets of GSE49515, GSE58208, GSE98269, GSE57957, and GSE49713, whereas PVT1 was downregulated in datasets of GSE54236 and GSE60502 ( Table 2 ). The Mean ± SD of each Table  2 .
PVT1 and HCC: A Metaanalysis of 840 Cases
After retrieving the datasets from the GEO database, 25 datasets were researched based on the keywords, and 18 datasets were excluded for not meeting our criteria. As a result, the meta-analysis included 840 cases from multiple centers (seven datasets from the GEO database [GSE54236, GSE49515, GSE60502, GSE58208, GSE98269, GSE57957 and GSE49713], the in-house RT-qPCR, and the original data in TCGA). The characteristics of these datasets included in the study are shown in Table 2 . As a result, the coalescent sensitivity and specificity of PVT1 were 0.59 (0.41-0.76) and 0.89 (0.71-0.96; Fig.  3A ), respectively. The DLR negative and DLR positive were 0.46 (0.31-0.69) and 5.27 (2.05-13.52, Fig. 3B ), respectively. The diagnostic score and odds ratio was 2.44 (1.38-3.51) and 11.49 (3.96-33.35 ; Fig.  3C ), respectively. The AUC of the summary ROC (SROC) was 0.81 (0.77-0.84; Fig. 4A ), which indicates that PVT1 could be of moderate value in discriminating HCC patients from normal controls. As for the publication bias, no significant publication bias was found (P = 0.77; Fig.  4B) .
As for the PVT1 expression in the HCC group compared with the normal group, a fixed-effects model was chosen to evaluate the 
Fig. 3. Diagnostic metaanalysis of PVT1 in HCC. (A)
The pooled sensitivity and specificity of the included studies, (B) the pooled positive DLR and negative DLR of the included studies, and (C) the pooled diagnostic score and diagnostic odds ratio of the included studies. Fig. 5A ). Then, a random-effects model was applied, and the combined SMD was 0.65 (0.17, 1.13) with a heterogeneity greater than 50% (Fig. 5B) . As for publication bias, no significant publication bias was found (P > 0.05; Fig. 5C ). In order to clarify whether a certain study contributed to the heterogeneity, a sensitivity analysis was applied to exclude two data sources (GSE54236 and the data in TCGA; Fig. 5D ). Then, the fixed-effects model showed the combined SMD was 0.44 (0.13, 0.74), indicating that a higher expression of PVT1 could be found in the HCC group than in the normal groups (Fig. 5E) .
In summary, the meta-analysis of PVT1 in HCC indicated that PVT1 was upregulated in HCC, and PVT1 has a moderate value in discriminating HCC patients from normal controls.
A Comprehensive Analysis of the Gene Expression Profile with Knockdown of PVT1
To explore the functions of PVT1 in the pathogenesis of HCC, we characterized a gene expression profile by silencing PVT1 expression. The light microscope and fluorescence microscope images after transfecting HCC cells with PVT1 RNAi are shown in Fig. 6A and Fig. 6B . The transfection efficiency was approximately 90%, and the knockdown efficiency of PVT1 in HCC cells was over 75% as detected by RT-qPCR (Fig. 6C) . Also, the expression of PVT1 in HCC cells was remarkably decreased in the Lv-siPVT1 group compared to the normal control group (P = 0.035) and the Lv-control group (P = 0.029; Fig. 6C ). Based on a gene microarray analysis, 195 upregulated genes and 60 downregulated genes were significantly 
Identification of the Corresponding miRNAs Associated with PVT1
In this study, five miRNAs (miR-139-5p, miR-199a-3p, miR-199a-5p, miR-29c-3p, miR-424-5p) were selected as overlapping miRNAs among the downregulated miRNAs in TCGA and GEO database. After verification by four miRNA prediction algorithms (Tarbase, starbase, lncACTdb, and TANRIC), miR-424-5p was the only overlapping miRNA that corresponded with PVT1 (Fig. 7A) . The complementary sequences between miR-424-5p and PVT1 are shown in Fig. 7B . To investigate the differential expression of miR-424-5p in HCC and noncancerous liver tissue, an RT-qPCR was performed. The results show that miR-424-5p was 
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clearly downregulated in HCC tissues compared with the corresponding non-tumor tissues (P < 0.001; Fig. 7C ). Furthermore, a ROC curve analysis was conducted to measure the value of miR-424-5p in HCC. The AUC of miR-424-5p was 0.767 (95% CI 0.660~0.874; P < 0.001; Fig. 7D ). Moreover, a negative correlation trend was found between miR-424-5p and PVT1 (r = -0.218; P = 0.183; Fig. 7E ). In addition, based on TCGA, we found that miR-424 was clearly downregulated in HCC tissues compared to normal liver tissues (P < 0.001; Fig. 7F) .
A ROC curve analysis was conducted to measure the value of miR-424 in HCC. The AUC of miR-424 was 0.978 (95% CI 0.965~0.991; P < 0.001; Fig. 7G ). We also tried to further study the relationship between miR-424 and clinicopathological parameters based on TCGA, but no positive results were found (Table 3) . Taken together, these results suggested that PVT1 might act as a miRNA sponge in HCC by targeting miR-424-5p.
Identification of the Corresponding Genes Associated with PVT1
To identify the key genes associated with PVT1 and miR-424-5p in HCC, only one gene expression profile (GSE57786) could be obtained from the GEO database, and the genes upregulated in GEO after PVT1 overexpression were screened out for subsequent evaluation. TCGA was searched to select the genes overexpressed in HCC. Additionally, the 60 downregulated genes after silencing PVT1 expression and the target genes of miR-424-5p predicted by more than five prediction algorithms were also considered to be candidate corresponding genes. As a result, only one gene-INCENP-was selected out of all the genes above via Venn diagrams (Fig. 8A) . Also, the complementary sequences between INCENP and miR-424-5p are shown in Fig. 8B . Based on data from TCGA, we found that INCENP was clearly upregulated in HCC tissues compared to normal liver tissues (P < 0.001, Fig. 8C ). Also, a positive correlation trend was found between PVT1 and INCENP (r = 0.039, P = 0.421, Fig. 8D ).
Considering the relationship between
INCENP and c l i n i c o p a t h o l o g i c a l parameters, we found that high INCENP expression was positively related to tumor stage (P = 0.007, Table 4 ). In addition, a ROC curve was drawn to evaluate the value of INCENP for HCC. The AUC of INCENP was 0.850 (95% CI 0.812~0.889; P < 0.001; Fig.  9D ). Additionally, we investigated the role of INCENP expression in patients' survival. It was observed that patients with low INCENP expression survived for longer (66.11 ± 4.55 months) compared to the high INCENP expression group (59.85 ± 5.36 months, P = 0.002, Fig. 9E ).
To further evaluate the proliferation of HCC cells in the four different groups (i.e., mock control, scrambled siRNA, INCENP siRNA 1, and INCENP siRNA 2.), an MTT assay and viability assay were performed to evaluate the proliferation of HCC cells. In the results of the MTT assay, HCC cells exhibited a large cell proliferation inhibition, especially in the INCENP siRNA groups at 72 h (P < 0.01, Fig. 10A ). Consistent with the results of the MTT assay, the viability assay showed a clear inhibition of growth in the INCENP siRNA groups at 72 h (P < 0.01; Fig. 10B ). Taken together, these results indicate that PVT1 might contribute to the progression of HCC by modulating INCENP.
According to TCGA, we confirmed that INCENP expression was higher in HCC than that in normal liver tissues. Additionally, the immunohistochemical results of INCENP were (Fig. 11) . Considering the limiting samples in HPA database, no statistical analysis could be carried out. However, INCENP protein could be found in some HCC cells and none of the non-HCC cells, which was consistent with the over-expressed pattern of INCENP from TCGA data.
The Upregulation of PVT1 Promotes HCC Cell Proliferation In vitro and Vivo
To further verify the biological function of PVT1 in HCC, we detected the cell growth capacity in HCC cells after silencing the expression of PVT1. The results of an MTT assay showed that Lv-siPVT1 clearly inhibited SMCC-7721 cell proliferation at 96 h (P < 0.05; Fig. 12A ). Furthermore, tumor formation experiments in a CAM model were conducted to evaluate the effect of PVT1 on tumorigenesis in vivo. The results showed that both the lvcontrol and PVT1-RNAi group could form tumors, and the tumorigenic ability of the PVT1-RNAi group was significantly weakened (P = 0.08, Fig. 12B ). 
The Potential Pathways Associated with PVT1 and miR-424-5p
In the current study, the GEO database, TCGA, a gene microarray, and prediction algorithms were all used to search for candidate genes, and 178 genes were selected for downstream analysis. Then, we explored the underlying gene functional pathways by GO and KEGG analyses based on these 178 genes. Consequently, cell division, protein kinase binding, as well as the kinesin complex were demonstrated to be strongly enriched biological terms that were closely associated with the progress of cancer (Table 5 ). To better comprehend the functions of these candidate genes, a function network was built based on the GO analysis (Fig. 13) .
In addition, the KEGG pathway analysis showed that these genes were significantly overrepresented in the cell cycle and p53 signaling pathway, supporting our aforementioned result that PVT1 might play a vital role in the proliferation of HCC cells (Table 6 ). Altogether, the GO and KEGG pathway items reinforced the observation that PVT1 might be involved in HCC's biological mechanisms.
In summary, we hypothesized that PVT1 could affect the biological function of HCC cells by targeting miR-424-5p and regulating INCENP, and the implementation of these biological functions might be involved in the p53 signaling pathway. However, various functional experiments should be conducted to verify the precise mechanism. Discussion lncRNAs are involved in regulating gene expression and widen our understanding of its biological functions in diseases, including cancers [33, 34] . Emerging evidence has demonstrated the functions of lncRNAs in HCC, including lncRNA-PVT1 [7] [8] [9] [10] 35] . As reported by xu et al., the overexpression of PVT1 in gastric cancer can predict the poor prognosis of gastric cancer patients and promote tumor cell proliferation and invasion via binding to FOXM1 [15] . Liu et al. also identified that PVT1 could serve as an oncogene in prostate cancer by activating the methylation of miR-146a and thereby promoting tumor growth [16] . Another study demonstrated that PVT1 expression was positively associated with tumor stage and metastasis, and increased expression of PVT1 could accelerate the progression of epithelial-mesenchymal transition (EMT) in esophageal cancer cells [36] . In addition, it has also been confirmed that the inhibition of PVT1 expression could enhance the sensitivity of cancer patients to drugs [17, 18, 37] . Despite this research, the role of PVT1 in HCC has remained elusive. Our present study was the first to combine the analysis of data from GEO, TCGA, and gene microarrays to illustrate the biological functions of PVT1 in HCC. In this research, we found that PVT1 was increased in HCC tissues and cell lines, which was consistent with the results found by Ding et al. and Yu et al. [35, 38] . In addition, this study was the first to use TCGA database to show that the upregulation of PVT1 in HCC tissues was highly associated with gender, race, and pathological grade. Ding et al.'s study demonstrated that the higher expression of PVT1 was strongly related with AFP level and predicted poor recurrencefree survival [38] . The paper written by Yu et al. indicated that the combined upregulation of two lncRNAs (PVT1 and uc002mbe.2) could provide a new method for the diagnosis of HCC, and the expression of PVT1 and uc002mbe.2 was positively related to tumor size and clinical stage in HCC patients [33] . Furthermore, Gou et al. found that PVT1 could promote cell proliferation and invasion in HCC by regulating miR-214 expression [39] . Moreover, this is the first meta-analysis to survey the expression and the potential value of PVT1 in HCC. The 0.55 SMD (0.38, 0.71) of this meta-analysis verified that HCC cells had high expressions of PVT1. Furthermore, in the diagnostic meta-analysis, 840 cases from GEO, TCGA, and inhouse RT-qPCR were included, and the results were analyzed to estimate the validity for the detection of PVT1 in HCC. The sensitivity of the PVT1 assay in the included parts ranged from 41% to 76%, and the specificity ranged from 71% to 96%. The combined sensitivity (0.77) and specificity (0.84) values demonstrated the accuracy of using PVT1 expression to detect HCC. Also, our results had an AUC of 0.81, which indicated that PVT1 could be of moderate value in discriminating HCC patients from normal controls [40] . A PLR value of 5.27 suggested that patients with HCC had an approximately 5.27-fold higher chance of being PVT1 assay-positive. However, there were some limitations in our meta-analysis. High heterogeneity could not be avoided partly because of blinding in the three included databases (GEO, TCGA, and in-house RT-qPCR), and we applied sensitivity analysis to exclude two data sources (GSE54236 and TCGA) to reduce heterogeneity. In addition, no adequate data from publications was found on the clinical value of PVT1 in HCC, which may be another limitation of our meta-analysis.
In addition, SMMC-7721 cells were transfected with siRNA-PVT1 to inhibit the expression of PVT1. Along with the knockdown of PVT1, the expression of 195 genes and 60 genes were respectively upregulated and downregulated. Then, we focused on the use of GEO, TCGA, a gene microarray and prediction algorithms, to identify miR-424-5p and INCENP as candidates for further analysis. We performed various experiments to confirm the role of PVT1, miR-424-5p, and INCENP in HCC. Taken the results together, we hypothesized that PVT1 could affect the biological function of HCC cells by targeting miR-424-5p and regulating INCENP. Focusing on this new insight into the PVT1/miR-424-5p/INCENP axis, this study provided a novel target for the clinical prevention of and therapeutic strategy for HCC.
As previously reported, miR-424-5p is related to the progression of different cancers [41] [42] [43] [44] . For example, Zhang et al. found that miR-424 was related to the pathological stage and poor prognosis of gastric cancer patients [41] . Wei et al. found that miR-424-5p could promote the proliferation of gastric cancer via targeting SMAD3 by the TGF-β signaling pathway [42] . Zhou et al. found that miR-424-5p could function as an anti-oncogene in the growth of cervical cancer cell by targeting KDM5B through the Notch signaling pathway [43] . Zhang et al. found that miR-424-5p was clearly downregulated in HCC tissues, and the low expression of miR-424-5p was critically correlated with higher pathological grades and TNM stages. Also, aberrant miR-424-5p expression is significantly involved in the progression of liver cancer [44] . Furthermore, growing evidence has confirmed the role of INCENP in cancers [45] [46] [47] . For example, Deng et al. confirmed that the methylation of INCENP could be involved in the growth of cancer cells [45] . Xia et al. demonstrated that the high expression of INCENP was associated with shorter survival in HCC patients [46] . Moreover, Adams et al. confirmed high INCENP levels in colon, testes, and prostate cancer cells [47] . In our current study, we verified the presence of the decreased expression of miR-424-5p and the overexpression of INCENP in HCC. Also, complementary sequences and the correlation between PVT1, miR-424-5p, and INCENP supported our hypothesis.
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In the pathway analysis, we found that overlapping genes were significantly overrepresented in the cell cycle and the p53 signaling pathway, supporting our results that PVT1 might play a vital role in the proliferation of HCC. The p53 signaling pathway is associated with the cell cycle, apoptosis, and poor prognosis for cancer patients [48] [49] [50] . These findings suggest that PVT1 affects the carcinogenesis and progression of HCC by modulating the expression of miR-424-5p and INCENP through the p53 signaling pathway.
Overall, our study indicated that PVT1 might serve as an oncogene to facilitate the progression of HCC by targeting miR-424-5p and regulating INCENP. However, the precise mechanism remains unknown, and further investigations are urgently needed.
